[The effect of primary lack of estrogens and the influence of the age at the beginning of estrogen therapy on bone mineral density in patients with Turner's syndrome].
Lumbar spine bone mineral density (BMD) values were measured in women with Turner's syndrome (TS) and the influence of primary ovarian failure as well as the age at the start of estroprogestins (EP) therapy were considered. EP treatment with 2mg of estradiol (E2) and BMD monitoring were started in 72 and finally continued for 5 years in 34 patients with TS, aged 12-38 years, previously not treated with growth hormone or anabolic steroids. The mean total BMD gain (deltaBMD) was 20% and the most significant increase was observed after the first (7.5%) and the second (6.6%) year of the therapy. Before the start and during EP treatment E2 levels were evaluated: they increased from 9.2pg/ml to the values observed in the controls (C) but positive correlation with BMD was not observed. Analysis of TS patients in age brackets (<15 years, 15-20 years, 21-25 years, >25 years) showed that only in the group that started EP treatment before the age of 15 every year significant deltaBMD was observed. The group that started EP therapy after the age of 20 didn't achieve significant deltaBMD. Patients wit TS had significantly higher levels of bone metabolism markers (Ntx and BALP) than the controls and in both groups negative correlation with age was found. On the basis of the results the conclusion was made that in hypoestrogenic women, not exclusively TS, the age when estrogen therapy is started may determine the effects in relation to bone mass. The administered E2 doses may also be important.
Sowińska-Przepiera
Elzbieta
E
Division of Gynecology, Department of Perinatology and Gynecology, Karol Marcinkowski University of Medical Sciences in Poznań. elasowprzep@wp.pl
Andrysiak-Mamos
Elzbieta
E
Friebe
Zbigniew
Z
Kapczuk
Karina
K
Pilarska
Krystyna
K
D015502:Absorptiometry, Photon; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D001827:Body Height / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000172:deficiency; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006803:Human Development / Q000187:drug effects; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D008137:Longitudinal Studies; D009652:Norpregnenes / Q000627:therapeutic use*; D011627:Puberty / Q000187:drug effects; D014424:Turner Syndrome / Q000188:drug therapy*
D004338:Drug Combinations; D004967:Estrogens; D009652:Norpregnenes; C494367:estroprogestin; D019382:Human Growth Hormone; D004997:Ethinyl Estradiol